Multiple Sclerosis: Diagnosis, Disease-Modifying Therapy, and Relapse Management

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) characterized by spatial and temporal dissemination of lesions. It affects approximately 2.8 million people worldwide, with peak onset between ages 20-40 years and a female predominance (3:1 ratio).

Pathophysiology: MS results from an autoimmune process targeting myelin sheaths, oligodendrocytes, and axons. The pathological hallmarks include:

• Inflammation: T-helper cells (Th1 and Th17) cross the blood-brain barrier and initiate inflammatory cascades
• Demyelination: Loss of myelin sheaths disrupts saltatory conduction
• Axonal damage: Progressive axonal loss leads to permanent disability
• Gliosis: Reactive astrocytic proliferation forms characteristic plaques

Clinical Phenotypes:

⚡ HIGH-YIELD: The McDonald Criteria emphasize demonstrating dissemination in space (DIS) and time (DIT) through clinical and/or MRI evidence. Early diagnosis and treatment initiation are crucial for preventing disability accumulation.

2017 Revised McDonald Criteria: Diagnosis requires demonstration of CNS lesions disseminated in space and time, with no better explanation for the clinical presentation.

Dissemination in Space (DIS) - requires ≥2 of:

• ≥1 T2-hyperintense lesion in periventricular regions
• ≥1 T2-hyperintense lesion in cortical/juxtacortical regions
• ≥1 T2-hyperintense lesion in infratentorial regions
• ≥1 T2-hyperintense lesion in spinal cord

Dissemination in Time (DIT) - demonstrated by:

• Simultaneous gadolinium-enhancing and non-enhancing lesions, OR
• New T2 and/or gadolinium-enhancing lesions on follow-up MRI, OR
• CSF-specific oligoclonal bands (if DIT not established by MRI)

Common Clinical Presentations:

Optic Neuritis (20-25%) ├── Unilateral vision loss ├── Pain with eye movement ├── Central scotoma └── Relative afferent pupillary defect

Spinal Cord Syndromes (25-30%) ├── Transverse myelitis ├── Lhermitte's sign ├── Sensory level dysfunction └── Bowel/bladder dysfunction

Brainstem/Cerebellar (15-20%) ├── Internuclear ophthalmoplegia ├── Diplopia ├── Vertigo └── Ataxia

Diagnostic Workup:

• MRI Brain and Spine: T2-FLAIR, T1 pre/post-gadolinium
• CSF Analysis: Oligoclonal bands, IgG index, cell count
• Visual Evoked Potentials: If optic neuritis suspected
• Laboratory: Vitamin B12, ANA, anti-AQP4, anti-MOG antibodies

⚠️ PEARL: Red flags suggesting alternative diagnoses include systemic symptoms, peripheral neuropathy, muscle pain, and symmetric presentations.

MRI Characteristics:

Gadolinium Enhancement Patterns:

• Ring enhancement: Active inflammatory lesions
• Homogeneous enhancement: Acute lesions (<8 weeks)
• Open ring sign: Characteristic of MS (incomplete ring)

CSF Analysis:

• Cell count: <50 cells/μL (predominantly lymphocytes)
• Protein: Mildly elevated (0.45-0.60 g/L)
• Glucose: Normal (2.2-3.9 mmol/L)
• Oligoclonal bands: Present in 85-95% of MS patients
• IgG index: >0.7 (normal <0.7)
• IgG synthesis rate: >3.3 mg/day (normal <3.3 mg/day)

Advanced MRI Techniques:

• Double inversion recovery (DIR): Enhanced cortical lesion detection
• Susceptibility-weighted imaging (SWI): Iron deposition assessment
• Diffusion tensor imaging (DTI): White matter tract integrity
• Magnetization transfer ratio (MTR): Myelin content quantification

Differential Diagnosis Considerations:

Inflammatory Demyelinating ├── ADEM (monophasic, children) ├── NMO (AQP4 antibodies) ├── MOG-associated demyelination └── Sarcoidosis

Vascular ├── CADASIL ├── Susac syndrome └── Primary CNS vasculitis

Infectious ├── Progressive multifocal leukoencephalopathy ├── HIV encephalitis └── Lyme disease

⚡ HIGH-YIELD: The presence of CSF oligoclonal bands not found in serum is highly supportive of MS diagnosis and can substitute for DIT evidence when MRI criteria are not met.

Injectable Therapies:

Oral Therapies:

Dimethyl fumarate (Tecfidera):

• Mechanism: Nrf2 pathway activation, anti-inflammatory
• Dosing: 120 mg BID × 7 days, then 240 mg BID
• Efficacy: 44-53% relapse reduction
• Monitoring: CBC, LFTs every 3 months; lymphocyte count
• Side effects: Flushing, GI upset, lymphopenia

Teriflunomide (Aubagio):

• Mechanism: Dihydroorotate dehydrogenase inhibitor
• Dosing: 14 mg daily
• Efficacy: 31% relapse reduction
• Monitoring: LFTs, CBC, blood pressure
• Contraindications: Pregnancy, severe hepatic impairment

Treatment Selection Considerations:

Patient Factors ├── Age and reproductive plans ├── Injection tolerance ├── Comorbidities └── Adherence preferences

Disease Factors ├── Relapse frequency/severity ├── MRI lesion burden ├── Disability progression └── Cognitive involvement

Monitoring Requirements:

• Baseline: CBC, CMP, LFTs, hepatitis B/C, VZV immunity
• Follow-up: Laboratory monitoring q3-6 months
• MRI: Annual brain MRI to assess treatment response
• Clinical: EDSS scoring, relapse documentation

⚠️ PEARL: Neutralizing antibodies can develop with interferon therapy (5-40% incidence), potentially reducing efficacy. Consider switching if high titer antibodies develop with clinical/radiological breakthrough activity.

Indications for High-Efficacy DMTs:

• Highly active RRMS despite first-line therapy
• Rapidly evolving severe RRMS (≥2 severe relapses in 1 year)
• Primary progressive MS with evidence of inflammation

Natalizumab (Tysabri):

• Mechanism: α4β1 integrin antagonist, blocks lymphocyte migration
• Dosing: 300 mg IV monthly
• Efficacy: 68% relapse reduction, 92% reduction in new T2 lesions
• Major Risk: Progressive multifocal leukoencephalopathy (PML)
• PML Risk Factors: JC virus seropositivity, prior immunosuppression, treatment duration >24 months

PML Risk Stratification:

Fingolimod (Gilenya):

• Mechanism: Sphingosine-1-phosphate receptor modulator
• Dosing: 0.5 mg daily
• Efficacy: 54% relapse reduction
• Monitoring: First-dose cardiac monitoring (6 hours), ophthalmologic exams
• Side Effects: Bradycardia, macular edema, infections, liver toxicity

Alemtuzumab (Lemtrada):

• Mechanism: Anti-CD52 monoclonal antibody
• Dosing: 12 mg/day × 5 days (year 1), 12 mg/day × 3 days (year 2)
• Efficacy: 49-55% relapse reduction vs interferon
• Secondary Autoimmunity: Thyroid disorders (30%), ITP (1%), anti-GBM disease (<1%)
• Monitoring: Monthly CBC, thyroid function, urinalysis for 4 years

Ocrelizumab (Ocrevus):

• Mechanism: Anti-CD20 monoclonal antibody
• Dosing: 300 mg IV × 2 doses (2 weeks apart), then 600 mg q6 months
• Efficacy: 46% relapse reduction (RRMS), first approved therapy for PPMS
• Side Effects: Infusion reactions, increased infection risk, breast cancer signal

Treatment Escalation Algorithm:

First-line DMT failure ├── Breakthrough activity definition │ ├── ≥1 relapse in 12 months │ ├── ≥2 new T2 or Gd+ lesions │ └── Significant disability progression ├── Escalation options │ ├── Switch to different platform │ ├── Escalate to high-efficacy DMT │ └── Consider combination therapy (investigational)

⚡ HIGH-YIELD: The "no evidence of disease activity" (NEDA-3) concept includes no relapses, no disability progression, and no MRI activity. This has become the therapeutic goal in modern MS management.

Definition of MS Relapse: Subjective report or objective observation of neurological dysfunction lasting ≥24 hours, preceded by neurological stability for ≥30 days, in the absence of fever or infection.

Pseudorelapse vs. True Relapse:

Acute Management Protocol:

High-dose Corticosteroids (First-line):

• Methylprednisolone: 1000 mg IV daily × 3-5 days
• Alternative: Prednisone 1250 mg PO daily × 3-5 days
• Mechanism: Anti-inflammatory, reduces blood-brain barrier permeability
• Efficacy: Accelerates recovery but no long-term disability benefit

Indications for Steroid Treatment:

• Moderate to severe functional impairment
• Optic neuritis with vision loss
• Motor weakness affecting activities of daily living
• Disabling ataxia or sensory symptoms

Plasma Exchange (Second-line):

• Indications: Severe relapses not responding to steroids
• Protocol: 5-7 exchanges over 10-14 days
• Mechanism: Removal of pathogenic antibodies and inflammatory mediators
• Evidence: Moderate improvement in 42-74% of steroid-refractory cases

Supportive Care During Relapses:

Symptom Management ├── Spasticity: Baclofen, tizanidine ├── Bladder dysfunction: Anticholinergics ├── Neuropathic pain: Gabapentin, pregabalin ├── Fatigue: Modafinil, amantadine └── Depression: SSRIs, counseling

Rehabilitation ├── Physical therapy ├── Occupational therapy ├── Speech therapy └── Cognitive rehabilitation

Recovery Patterns:

• Complete recovery: Return to baseline function (more common early in disease)
• Incomplete recovery: Residual deficit contributing to disability accumulation
• Recovery timeline: Usually begins within 2-4 weeks, continues for 2-6 months

When NOT to treat with steroids:

• Mild sensory symptoms without functional impact
• Fatigue or cognitive symptoms alone
• Symptoms lasting <24 hours
• Presence of active infection
• Poorly controlled diabetes mellitus

⚠️ PEARL: Oral and IV steroids show equivalent efficacy for MS relapses. The choice depends on severity, patient preference, and ability to tolerate oral medication. Consider IV route for severe visual loss or brainstem symptoms.

Comprehensive Care Framework:

Clinical Monitoring:

• Frequency: Every 3-6 months for stable patients, more frequent during relapses or treatment changes
• EDSS Assessment: Standardized disability scoring (0-10 scale)
• Functional assessments: Timed 25-foot walk, 9-hole peg test, Symbol Digit Modalities Test
• Quality of life measures: MSQOL-54, Fatigue Severity Scale

MRI Surveillance Schedule:

Symptom Management Strategies:

Fatigue (80-90% of patients):

• Pharmacological: Modafinil 100-200 mg daily, Amantadine 100 mg BID
• Non-pharmacological: Energy conservation, exercise programs, cooling therapy
• Rule out: Depression, sleep disorders, medication side effects

Spasticity:

• Mild: Stretching, physical therapy
• Moderate: Baclofen 5-20 mg TID, Tizanidine 2-8 mg TID
• Severe: Intrathecal baclofen pump, botulinum toxin injections

Bladder Dysfunction (>80% prevalence):

• Overactive bladder: Oxybutynin, tolterodine, mirabegron
• Urinary retention: Intermittent catheterization
• Evaluation: Post-void residual, urodynamics if complex

Cognitive Impairment (40-70% prevalence):

• Assessment: Montreal Cognitive Assessment (MoCA), neuropsychological testing
• Management: Cognitive rehabilitation, pharmacological trials (limited evidence)
• Monitoring: Annual screening in high-risk patients

Vaccination and Infection Prevention:

Vaccination Schedule ├── Annual influenza vaccine ├── COVID-19 vaccines (per guidelines) ├── Pneumococcal vaccines └── Live vaccines contraindicated during immunosuppression

Infection Monitoring ├── Regular screening for opportunistic infections ├── Hepatitis B/C monitoring ├── JC virus serology (natalizumab patients) └── Prompt treatment of infections

Pregnancy Considerations:

• DMT management: Most DMTs require discontinuation
• Safe options: Glatiramer acetate, certain interferons
• Relapse risk: Decreased during pregnancy, increased postpartum
• Monitoring: Increased surveillance in third trimester and postpartum period

Transition to Progressive Phase:

• Recognition: Sustained disability progression independent of relapses
• Management: Focus on symptom management, rehabilitation
• Emerging therapies: Siponimod for SPMS, ocrelizumab for PPMS

⚡ HIGH-YIELD: The concept of "brain reserve" emphasizes the importance of maintaining cognitive function through intellectual activities, physical exercise, and optimal management of comorbidities throughout the disease course.